LEADER 02868nam 2200469 450 001 9910717366803321 005 20221026083814.0 035 $a(CKB)4100000006098611 035 $a(NjHacI)994100000006098611 035 $a(OCoLC)858650008$z(OCoLC)878436098$z(OCoLC)1117861391 035 $a(EXLCZ)994100000006098611 100 $a20221026d2012 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aTreatment of metastatic non-small cell lung cancer $ea systematic review of comparative effectiveness and cost-effectiveness /$fPaul G. Shekelle [and three others] 210 1$aWashington, DC :$cDepartment of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Reseach & Development Service,$d2012. 210 4$dİ2012 215 $a1 online resource (iv, 82 pages) $cillustrations 300 $a"Evidence-based synthesis program." 300 $a"October 2012." 320 $aIncludes bibliographical references. 330 3 $aLung cancer is the leading cause of cancer death in both men and women in the United States, and male Veterans seeking care at VA hospitals have a much higher age-specific incidence of lung cancer than males in the general population. The personal and economic significance of lung cancer has led to a vast research endeavor to try and identify new and more effective treatments. Most patients with lung cancer are diagnosed when the cancer is already advanced (stage IIIB or IV), and they are no longer candidates for surgical resection. Small cell lung cancer and non-small cell lung cancer (NSCLC) are different diseases in terms of treatment. Until recently, all therapies for advanced NSCLC were based on their cytotoxic properties. In the last few years, several novel agents aimed at specific molecular targets have been developed. This review was requested to evaluate the current evidence on the effectiveness and cost-effectiveness of treatments for advanced lung cancer. 517 $aTreatment of metastatic non-small cell lung cancer 606 $aLungs$xCancer 607 $aUnited States$2fast 608 $aTechnical reports.$2lcgft 615 0$aLungs$xCancer. 676 $a616.99424 700 $aShekelle$b Paul G.$01236354 712 02$aUnited States.$bDepartment of Veterans Affairs.$bHealth Services Research and Development Service, 712 02$aWest Los Angeles VA Medical Center.$bEvidence-Based Synthesis Program Center. 712 02$aQuality Enhancement Research Initiative (U.S.) 712 02$aEvidence-based Synthesis Program (U.S.) 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910717366803321 996 $aTreatment of metastatic non-small cell lung cancer$93314968 997 $aUNINA